Skip to main navigation Skip to search Skip to main content

Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy

  • Rowan T. Chlebowski
  • , Garnet Anderson
  • , Mary Pettinger
  • , Dorothy Lane
  • , Robert D. Langer
  • , Mary Ann Gillian
  • , Brian W. Walsh
  • , Chu Chen
  • , Anne McTiernan
  • University of California at Los Angeles
  • Fred Hutchinson Cancer Research Center
  • University of San Diego
  • Medical College of Wisconsin
  • Brigham and Women’s Hospital

Research output: Contribution to journalArticlepeer-review

91 Scopus citations

Abstract

Background: The effect of combined hormone therapy on breast cancer detection is not established. Methods: We examined the effect of combined hormone therapy on breast cancer detection in the Women's Health Initiative trial, which randomized 16 608 postmenopausal women to receive conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d) or placebo. Mammography and breast examinations were performed at baseline and annually per protocol, with breast biopsies based on clinical findings. The effects of conjugated equine estrogens plus medroxyprogesterone acetate on breast cancer detection was determined throughout 5.6 years of intervention using receiver operating characteristic analyses to evaluate mammography results. Results: Conjugated equine estrogens plus medroxyprogesterone acetate increased the cumulative frequency of mammograms with abnormalities vs placebo (35.0% vs 23.0%; P<.001), which had less sensitivity for cancer detection and increased cumulative breast biopsy frequency (10.0% vs 6.1%; P<.001). Although breast cancers were significantly increased and were diagnosed at higher stages in the combined hormone group, biopsies in that group less frequently diagnosed cancer (14.8% vs 19.6%; P=.006). After discontinuation of combined hormone therapy, its adverse effect on mammograms modulated but remained significantly different from that of placebo for at least 12 months (P<.001). Conclusions: Use of conjugated equine estrogens plus medroxyprogesterone acetate for approximately 5 years resulted in more than 1 in 10 and 1 in 25 women having otherwise avoidable mammogram abnormalities and breast biopsies, respectively, and compromised the diagnostic performance of both. This adverse effect on breast cancer detection should be incorporated into risk-benefit discussions with women considering even shortterm combined hormone therapy. Trial Registration: clinicaltrials.gov Identifier: NCT00000611

Original languageEnglish
Pages (from-to)370-377
Number of pages8
JournalArchives of Internal Medicine
Volume168
Issue number4
DOIs
StatePublished - Feb 25 2008

Fingerprint

Dive into the research topics of 'Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy'. Together they form a unique fingerprint.

Cite this